3
Announcements
Trials
Browse
Landscape
Status
Recruiting
52
Completed
35
Active not recruiting
31
Terminated
11
Not yet recruiting
10
Suspended
1
Enrolling by invitation
1
Available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Neoplasms
8
Carcinoma, Non-Small-Cell Lung
7
Pancreatic Neoplasms
6
Sarcoma
5
Prostatic Neoplasms
5
Recurrence
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Ovarian Neoplasms
4
Neuroblastoma
4
Multiple Myeloma
4
Breast Neoplasms
4
Melanoma
3
Lymphoma, Large B-Cell, Diffuse
3
Leukemia, Myeloid, Acute
3
Hematologic Neoplasms
3
Head and Neck Neoplasms
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Primary Myelofibrosis
2
Osteosarcoma
2
Non-Muscle Invasive Bladder Neoplasms
2
Neuroectodermal Tumors, Primitive
2
Myelodysplastic Syndromes
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Follicular
2
Lymphoma
2
Insulinoma
2
Hypoglycemia
2
Hyperinsulinism
2
Interventions
asciminib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Available
×
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
1 year
×
Clear all
NCT04360005
2025-12-05
Managed Access Programs for ABL001, Asciminib
Novartis
Available